Sensorium Therapeutics
BOSTON, MA · Healthcare, Health Care · 27 employees
Sensorium embraces the biological complexity of the human brain and nature to develop breakthrough medicines to address a growing unmet medical need in mental health and neurological diseases.
Funding history
- Funding Round — $26.8M — Jul 2025
- Funding Round — $14.5M — Feb 2025
- Funding Round — $24.7M — Dec 2023
- Series series a — $30.0M — Nov 2022
- Funding Round — $15.5M — Oct 2022
Recent signals
- May 27, 2026: Sensorium Therapeutics Appoints Cole Brown, M.D. as Chief Medical Officer
- Jul 15, 2025: Raised $26.8M
- Feb 12, 2025: Raised $14.5M
- Apr 17, 2024: Sensorium Therapeutics Appoints Sam Rasty, Ph.D., as Chief Business Officer
- Dec 06, 2023: Raised $24.7M
- Dec 04, 2023: Sensorium Therapeutics Announces Appointment of Veteran Biotech Executive Alexandra Glucksmann, Ph.D., as CEO as the Company Progresses Toward the Clinic
- Nov 08, 2022: Raised $30.0M in Series series a
- Oct 04, 2022: Raised $15.5M
See plans & pricing → Track Sensorium Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.